Castrate Resistant Prostate Cancer Market By Drug Class (Androgen Receptor (AR) Inhibitors, CYP17 Inhibitors, Chemotherapy Agents, Immunotherapy Agents, Radiopharmaceuticals, Others), By Therapy Type (Hormonal Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By End-User (Hospitals, Specialty Clinics, Homecare), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Castrate-Resistant Prostate Cancer Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Increasing prevalence of prostate cancer and aging population driving demand for advanced treatments

3.2.2. Ongoing advancements in targeted therapies and precision medicine improving treatment efficacy and outcomes

3.2.3. Rising awareness and diagnosis rates due to improved screening technologies and patient education campaigns

3.3. Key industry pitfalls & challenges

3.3.1. High cost of novel therapies limiting access for patients in low- and middle-income countries

3.3.2. Limited availability of effective treatment options for late-stage or metastatic CRPC cases

3.3.3. Stringent regulatory approvals and long development timelines hindering rapid drug commercialization

3.4. Market Opportunities

3.4.1. Expanding pipeline of innovative drugs, including combination therapies, for better patient outcomes

3.4.2. Growth in emerging markets offering untapped potential for cancer treatment adoption and awareness

3.4.3. Integration of biomarkers and companion diagnostics enhancing personalized medicine approaches in cancer care

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Castrate-Resistant Prostate Cancer Market, Drug Class Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Drug Class, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Androgenic Receptor (AR) Inhibitors

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. CYP17 Inhibitors

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Chemotherapy Agents

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Immunotherapy Agents

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Radiopharmaceuticals

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.7. Others

4.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Castrate-Resistant Prostate Cancer Market, Therapy Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Therapy Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Hormonal Therapy

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Chemotherapy

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Targeted Therapy

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Immunotherapy

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Castrate-Resistant Prostate Cancer Market, End-User Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By End-User, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Hospitals

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Specialty Clinics

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Homecare

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Castrate-Resistant Prostate Cancer Market, Region Segment Analysis

7.1. Overview

7.1.1. Global Market Revenue Share, By Region, 2025 & 2035

7.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

7.2. North America

7.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

7.2.2. North America Market Revenue, By Drug Class, 2025-2035

7.2.3. North America Market Revenue, By Therapy Type, 2025-2035

7.2.4. North America Market Revenue, By End-User, 2025-2035

7.2.5. The U.S.

7.2.5.1. U.S. Market Revenue, By Drug Class, 2025-2035

7.2.5.2. U.S. Market Revenue, By Therapy Type, 2025-2035

7.2.5.3. U.S. Market Revenue, By End-User, 2025-2035

7.2.6. Canada

7.2.6.1. Canada Market Revenue, By Drug Class, 2025-2035

7.2.6.2. Canada Market Revenue, By Therapy Type, 2025-2035

7.2.6.3. Canada Market Revenue, By End-User, 2025-2035

7.3. Europe

7.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

7.3.2. Europe Market Revenue, By Drug Class, 2025-2035

7.3.3. Europe Market Revenue, By Therapy Type, 2025-2035

7.3.4. Europe Market Revenue, By End-User, 2025-2035

7.3.5. Germany

7.3.5.1. Germany Market Revenue, By Drug Class, 2025-2035

7.3.5.2. Germany Market Revenue, By Therapy Type, 2025-2035

7.3.5.3. Germany Market Revenue, By End-User, 2025-2035

7.3.6. France

7.3.6.1. France Market Revenue, By Drug Class, 2025-2035

7.3.6.2. France Market Revenue, By Therapy Type, 2025-2035

7.3.6.3. France Market Revenue, By End-User, 2025-2035

7.3.7. U.K.

7.3.7.1. U.K. Market Revenue, By Drug Class, 2025-2035

7.3.7.2. U.K. Market Revenue, By Therapy Type, 2025-2035

7.3.7.3. U.K. Market Revenue, By End-User, 2025-2035

7.3.8. Italy

7.3.8.1. Italy Market Revenue, By Drug Class, 2025-2035

7.3.8.2. Italy Market Revenue, By Therapy Type, 2025-2035

7.3.8.3. Italy Market Revenue, By End-User, 2025-2035

7.3.9. Spain

7.3.9.1. Spain Market Revenue, By Drug Class, 2025-2035

7.3.9.2. Spain Market Revenue, By Therapy Type, 2025-2035

7.3.9.3. Spain Market Revenue, By End-User, 2025-2035

7.3.10. Rest of Europe

7.3.10.1. Rest of Europe Market Revenue, By Drug Class, 2025-2035

7.3.10.2. Rest of Europe Market Revenue, By Therapy Type, 2025-2035

7.3.10.3. Rest of Europe Market Revenue, By End-User, 2025-2035

7.4. Asia Pacific

7.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

7.4.2. Asia Pacific Market Revenue, By Drug Class, 2025-2035

7.4.3. Asia Pacific Market Revenue, By Therapy Type, 2025-2035

7.4.4. Asia Pacific Market Revenue, By End-User, 2025-2035

7.4.5. China

7.4.5.1. China Market Revenue, By Drug Class, 2025-2035

7.4.5.2. China Market Revenue, By Therapy Type, 2025-2035

7.4.5.3. China Market Revenue, By End-User, 2025-2035

7.4.6. Japan

7.4.6.1. Japan Market Revenue, By Drug Class, 2025-2035

7.4.6.2. Japan Market Revenue, By Therapy Type, 2025-2035

7.4.6.3. Japan Market Revenue, By End-User, 2025-2035

7.4.7. India

7.4.7.1. India Market Revenue, By Drug Class, 2025-2035

7.4.7.2. India Market Revenue, By Therapy Type, 2025-2035

7.4.7.3. India Market Revenue, By End-User, 2025-2035

7.4.8. Australia

7.4.8.1. Australia Market Revenue, By Drug Class, 2025-2035

7.4.8.2. Australia Market Revenue, By Therapy Type, 2025-2035

7.4.8.3. Australia Market Revenue, By End-User, 2025-2035

7.4.9. South Korea

7.4.9.1. South Korea Market Revenue, By Drug Class, 2025-2035

7.4.9.2. South Korea Market Revenue, By Therapy Type, 2025-2035

7.4.9.3. South Korea Market Revenue, By End-User, 2025-2035

7.4.10. Singapore

7.4.10.1. Singapore Market Revenue, By Drug Class, 2025-2035

7.4.10.2. Singapore Market Revenue, By Therapy Type, 2025-2035

7.4.10.3. Singapore Market Revenue, By End-User, 2025-2035

7.4.11. Rest of Asia Pacific

7.4.11.1. Rest of Asia Pacific Market Revenue, By Drug Class, 2025-2035

7.4.11.2. Rest of Asia Pacific Market Revenue, By Therapy Type, 2025-2035

7.4.11.3. Rest of Asia Pacific Market Revenue, By End-User, 2025-2035

7.5. Latin America

7.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

7.5.2. Latin America Market Revenue, By Drug Class, 2025-2035

7.5.3. Latin America Market Revenue, By Therapy Type, 2025-2035

7.5.4. Latin America Market Revenue, By End-User, 2025-2035

7.5.5. Brazil

7.5.5.1. Brazil Market Revenue, By Drug Class, 2025-2035

7.5.5.2. Brazil Market Revenue, By Therapy Type, 2025-2035

7.5.5.3. Brazil Market Revenue, By End-User, 2025-2035

7.5.6. Argentina

7.5.6.1. Argentina Market Revenue, By Drug Class, 2025-2035

7.5.6.2. Argentina Market Revenue, By Therapy Type, 2025-2035

7.5.6.3. Argentina Market Revenue, By End-User, 2025-2035

7.5.7. Mexico

7.5.7.1. Mexico Market Revenue, By Drug Class, 2025-2035

7.5.7.2. Mexico Market Revenue, By Therapy Type, 2025-2035

7.5.7.3. Mexico Market Revenue, By End-User, 2025-2035

7.5.8. Rest of Latin America

7.5.8.1. Rest of Latin America Market Revenue, By Drug Class, 2025-2035

7.5.8.2. Rest of Latin America Market Revenue, By Therapy Type, 2025-2035

7.5.8.3. Rest of Latin America Market Revenue, By End-User, 2025-2035

7.6. MEA

7.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

7.6.2. MEA Market Revenue, By Drug Class, 2025-2035

7.6.3. MEA Market Revenue, By Therapy Type, 2025-2035

7.6.4. MEA Market Revenue, By End-User, 2025-2035

7.6.5. GCC Countries

7.6.5.1. GCC Countries Market Revenue, By Drug Class, 2025-2035

7.6.5.2. GCC Countries Market Revenue, By Therapy Type, 2025-2035

7.6.5.3. GCC Countries Market Revenue, By End-User, 2025-2035

7.6.6. South Africa

7.6.6.1. South Africa Market Revenue, By Drug Class, 2025-2035

7.6.6.2. South Africa Market Revenue, By Therapy Type, 2025-2035

7.6.6.3. South Africa Market Revenue, By End-User, 2025-2035

7.6.7. Rest of Middle East & Africa

7.6.7.1. Rest of Middle East & Africa Market Revenue, By Drug Class, 2025-2035

7.6.7.2. Rest of Middle East & Africa Market Revenue, By Therapy Type, 2025-2035

7.6.7.3. Rest of Middle East & Africa Market Revenue, By End-User, 2025-2035

8. Company Profile

8.1. Johnson & Johnson

8.1.1. Business Overview

8.1.2. Financial Performance

8.1.3. Product/Service Offerings

8.1.4. Strategies & recent developments

8.1.5. SWOT Analysis

8.2. Astellas Pharma

8.2.1. Business Overview

8.2.2. Financial Performance

8.2.3. Product/Service Offerings

8.2.4. Strategies & recent developments

8.2.5. SWOT Analysis

8.3. Sanofi

8.3.1. Business Overview

8.3.2. Financial Performance

8.3.3. Product/Service Offerings

8.3.4. Strategies & recent developments

8.3.5. SWOT Analysis

8.4. Bayer

8.4.1. Business Overview

8.4.2. Financial Performance

8.4.3. Product/Service Offerings

8.4.4. Strategies & recent developments

8.4.5. SWOT Analysis

8.5. Pfizer

8.5.1. Business Overview

8.5.2. Financial Performance

8.5.3. Product/Service Offerings

8.5.4. Strategies & recent developments

8.5.5. SWOT Analysis

8.6. AstraZeneca

8.6.1. Business Overview

8.6.2. Financial Performance

8.6.3. Product/Service Offerings

8.6.4. Strategies & recent developments

8.6.5. SWOT Analysis

8.7. Novartis

8.7.1. Business Overview

8.7.2. Financial Performance

8.7.3. Product/Service Offerings

8.7.4. Strategies & recent developments

8.7.5. SWOT Analysis

8.8. Merck & Co.

8.8.1. Business Overview

8.8.2. Financial Performance

8.8.3. Product/Service Offerings

8.8.4. Strategies & recent developments

8.8.5. SWOT Analysis

8.9. Bristol-Myers Squibb

8.9.1. Business Overview

8.9.2. Financial Performance

8.9.3. Product/Service Offerings

8.9.4. Strategies & recent developments

8.9.5. SWOT Analysis

8.10. Ipsen

8.10.1. Business Overview

8.10.2. Financial Performance

8.10.3. Product/Service Offerings

8.10.4. Strategies & recent developments

8.10.5. SWOT Analysis

8.11. Eli Lilly and Co.

8.11.1. Business Overview

8.11.2. Financial Performance

8.11.3. Product/Service Offerings

8.11.4. Strategies & recent developments

8.11.5. SWOT Analysis

8.12. Amgen

8.12.1. Business Overview

8.12.2. Financial Performance

8.12.3. Product/Service Offerings

8.12.4. Strategies & recent developments

8.12.5. SWOT Analysis

8.13. AbbVie

8.13.1. Business Overview

8.13.2. Financial Performance

8.13.3. Product/Service Offerings

8.13.4. Strategies & recent developments

8.13.5. SWOT Analysis

8.14. Takeda Pharmaceutical Company

8.14.1. Business Overview

8.14.2. Financial Performance

8.14.3. Product/Service Offerings

8.14.4. Strategies & recent developments

8.14.5. SWOT Analysis

8.15. OncoOne

8.15.1. Business Overview

8.15.2. Financial Performance

8.15.3. Product/Service Offerings

8.15.4. Strategies & recent developments

8.15.5. SWOT Analysis

8.16. Clovis Oncology

8.16.1. Business Overview

8.16.2. Financial Performance

8.16.3. Product/Service Offerings

8.16.4. Strategies & recent developments

8.16.5. SWOT Analysis

8.17. Bayer HealthCare Pharmaceuticals

8.17.1. Business Overview

8.17.2. Financial Performance

8.17.3. Product/Service Offerings

8.17.4. Strategies & recent developments

8.17.5. SWOT Analysis

8.18. Roche

8.18.1. Business Overview

8.18.2. Financial Performance

8.18.3. Product/Service Offerings

8.18.4. Strategies & recent developments

8.18.5. SWOT Analysis

8.19. Exelixis

8.19.1. Business Overview

8.19.2. Financial Performance

8.19.3. Product/Service Offerings

8.19.4. Strategies & recent developments

8.19.5. SWOT Analysis